🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: 68Ga-PSMA-617

Found 43 matching trials

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

PHASE1

The purpose of this study is to evaluate the change in the expression of tr...

Status

Active Not Recruiting

Location

Nebraska Cancer Specialists

Start Date

2024-07-29

Trial ID

NCT06379217

Treatments Being Tested

[68Ga]Ga-PSMA-11 [68Ga]GA-DOTA-TATE [68Ga]Ga-NeoB [177Lu]Lu-PSMA-617 [177Lu]Lu-DOTA-TATE [177Lu]Lu-NeoB L-Lysine HCl-L-Arginine HCl, 2.5 %,Gonadotropin-releasing hormone (GnRH) analogues GnRH antagonists Antiemetics & antinauseants Metoclopramide

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

PHASE2

In advanced metastatic castration resistant prostate cancer (mCRPC) progres...

Status

Recruiting

Location

UCLA / Jonsson Comprehensive Cancer Center

Start Date

2024-08-01

Trial ID

NCT06216249

Treatments Being Tested

Computed Tomography Gallium Ga 68 Gozetotide Lutetium Lu 177 Vipivotide Tetraxetan Positron Emission Tomography PSMA PET Scan Questionnaire Administration Single Photon Emission Computed Tomography

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

PHASE2

The purpose of this study is to assess the efficacy, tolerability, safety, ...

Status

Completed

Location

Novartis Investigative Site

Start Date

2022-01-25

Trial ID

NCT05114746

Treatments Being Tested

177Lu-PSMA-617 68Ga-PSMA-11 Best supportive/best standard of care

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

PHASE3

This phase III study provides access to 68Ga-PSMA-11 positron emission tomo...

Status

Completed

Location

Mayo Clinic in Rochester

Start Date

2022-05-09

Trial ID

NCT05547386

Treatments Being Tested

Computed Tomography Gallium Ga 68 Gozetotide Positron Emission Tomography

Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

PHASE2

18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emiss...

Status

Unknown

Location

Peking Union Medical College Hospital

Start Date

2021-07-01

Trial ID

NCT05841992

Treatments Being Tested

Al18F-PSMA-617 68Ga-PSMA-617

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

PHASE2

This phase II trial studies how to improve the usage of Lu 177 vipivotide t...

Status

Suspended

Location

Mayo Clinic in Rochester

Start Date

2024-05-03

Trial ID

NCT06200103

Treatments Being Tested

Biospecimen Collection Bone Scan Clinical Observation Computed Tomography Gallium Ga 68 Gozetotide Lutetium Lu 177 Vipivotide Tetraxetan Positron Emission Tomography Questionnaire Administration Single Photon Emission Computed Tomography

Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer

The purpose of this study is to determine the pharmacokinetics, dosimetry, ...

Status

Unknown

Location

68Ga-PSMA-33 PET/CT imaging

Start Date

2022-10-01

Trial ID

NCT06054789

Treatments Being Tested

68Ga-PSMA-33

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE1

This phase I trial studies the safety, side effects, and treatment cycle 1 ...

Status

Not Yet Recruiting

Location

University of Michigan Rogel Cancer Center

Start Date

2026-08-01

Trial ID

NCT07682649

Treatments Being Tested

Biospecimen Collection Computed Tomography Gallium Ga 68 Gozetotide Lutetium Lu 177 Vipivotide Tetraxetan Positron Emission Tomography Questionnaire Administration Single Photon Emission Computed Tomography Technetium Tc-99m Sulfur Colloid

Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.

Patients undergo three diagnostic PET scans: 18F-FDG PET scan / 18F-Choline...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2024-01-31

Trial ID

NCT06136377

Treatments Being Tested

177Lu-PSMA-617 PET scan

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

N/A

The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-...

Status

No Longer Available

Location

Multiple Locations

Start Date

TBD

Trial ID

NCT04825652

Treatments Being Tested

177Lu-PSMA-617 PSMA-11

Previous Next